• Developed an artificial intelligence system for the management of AIDS
• Helped develop the concept of immune system reconstitution in many diseases
• Established models of viral-induced diabetes and heart disease
• Discovered or established the role of viruses in several diseases:
  • ALS virus
  • PPS virus
  • Retrovirus in Lupus
  • HHV-6 in CFS
  • HHV-6 in MS
• Developed an oral system for vaccine delivery
• Established the role of low Natural Killer Cell function in several chronic diseases
• Validated the use of bioassays in the study of natural products
• Determined conditions under which neuronal regeneration is possible

My research accomplishments include the discovery of a virus which may cause Amylotropic Lateral Sclerosis (ALS), known in the United States as Lou Gehrig’s disease. I've also shown that viruses are associated with such diseases as diabetes, certain forms of heart disease, chronic fatigue syndrome, and post-polio syndrome (PPS). I was a member of the team that developed a computer artificial intelligence system for the management of AIDS. I've also worked extensively in the area of vaccine development. My current efforts are focused on the use of established scientific methods to test the purity, toxicity, and benefits of natural products; and the use of natural products to slow or reverse the aging process, protect the health of persons without chronic diseases, and assist in the management of patients with chronic diseases.

Infectious Diseases, 11/92

• From 7/92 to 10/98. Assistant/Associate Clinical Professor of Medicine
• From 7/92 to 10/98. Investigator, California Collaborative Treatment Group
• From 7/94 to 10/98. Infectious Disease Consultant, Liver Transplantation Service

• 7/92-12/93. Chair, Infection Control Committee, Western Medical Center, Anaheim
• Since 10/97. Member, Orange County HIV client services committee
• From 9/97 to 8/98. Medical Expert, Pasadena County Court of Appeals, Judge Philip Simon
• From 6/96 to 8/98. Consultant, Center for Special Immunology
• From 1/98 to 10/98. Member, Orange County AIDS Planning Advisory Board
• Since 1/98. Co-chair, Research Division, American Neutraceutical Association
• Since 3/99. Director, Orange County Institute of Longevity Medicine

• Republican Senatorial inner circle
• Recipient, Republican Senatorial Medal of Freedom, 1999

• Alpha Omega Alpha Society
• Winner, Department of Medicine Fellow's Research Competition, 1991 and 1992

• Immunological Letters
• Nutritional and Agricultural Immunity
  

1. A Randomized Placebo-Controlled Trial of E-5 Monoclonal Antibody in patients with Severe Sepsis, Pfizer Pharmaceuticals, 9/93, $137,500
2. Randomized, Double-Blind, Placebo-Controlled Comparative Dose Response Study of Two Doses of Atevirdine Mesylate in Combination with Fixed Doses of Zidovudine in HIV + Patients, Upjohn Pharmaceuticals, 10/93, $65,202
3. Study of Natural Killer Cell Function in HIV + Individuals (Unlimited Grant), Schering Pharmaceuticals, 10/93, $15,000
4. AIDS education grant, Roche Pharmaceuticals, 8/93, $1,250
5. A Double-Blind, Randomized, Dose-Response Study of Three Fixed Doses of Delavirdine Mesylate in Combination with Zidovudine versus Zidovudine alone in HIV-1 Infected Individuals with CD4 Counts of 200-500/mm3, Upjohn Pharmaceuticals, 2/94, $165,400
6. A Double-Blind, Randomized, Comparative Study of Three Fixed Doses of Delavirdinze Mesylate in Combination with Didanosine versus Didanosine alone in HIV-1 Infected Individuals with CD4 Counts of <300/mm3, Upjohn Pharmaceuticals, 2/94, $166,960
7. Development of a Rapid Immunoassay for the Detection of Antibodies to HIV, Harvard Biotechnology, 7/94, $20,000
8. Alpha Interferon Treatment of Patients with Deficiency in Natural Killer Cell Function (Unlimited Grant), Schering Pharmaceuticals, 8/94, $5,500
9. Detection of Antibodies to HIV in Saliva, Trinity Biotechnology, 9/94,$1,000
10. Career Development Award, 4/95, $1,000
11. Study of the immunomodulatory effects of HANSI in mice (Unlimited Grant), HANSI International, 6/95, $19,200
12. Rapid Detection of Antibodies to HIV, Worldwide Medical Corporation, 10/96, $81,955
13. Molecular Biology Training Grant (at the WHO Virology Reference Laboratory in Lyon, France), Biosphere Technology, 5/96-10/96, $22,500
14. Development of an Expert System in the management in HIV-infected individuals, California Collaborative Treatment Group, $15,000
15. Application of an Expert System in the management of HIV-infected individuals, Roche Molecular Systems, $59,600
16. Motor Control in Chronic Fatigue Syndrome (sub-investigator), National Institutes of Health R01 grant, 1/98-1/01, $640,270
17. The utility of GM-CSF in preventing opportunistic infections in patients with AIDS, Immunex Co., 9/97, $75,400
18. Use of Remune in enhancing HIV-specific immune responses in HIV-infected patients with CD4 counts > 400, Immune Response Co., 6/97, $48,000
19. Use of an augmented expert system display in the management of HIV-infected patients, Roche Molecular Systems, 1/98, $63,400
20. Validation of nucleoprotein gene tracking for the detection of Mycoplasma Incognitus, Department of Defense, 1/98, $12,500
21. Use of PGE-1 as a vasodilator, 7/98, Harvard Scientific, $15,000.
22. Immunomodulatory effects of glyconutrients, 7/98, Mannatech Inc, 32,000.

• Presentations at Professional Meetings

• Treatment of Coxsackievirus A9 Myocarditis in Mice with WIN 54954: American College of Physicians (ACP) 6/91 Intersciences Conference on Antimicrobial Agents and Chemotherapy, ICAAC, 1991
• Treatment of Viral-induced Diabetes in Mice: ICAAC, 1992
• Pathogenesis of Viral-Induced Diabetes in Mice: ICAAC, 1993
• Alpha Interferon Treatment of Patients with Chronic Fatigue Syndrome: ICAAC, 1994
• First Check HIV 1-2, a two-step, five minute whole blood immunochromatographic assay to detect HIV 1-2 antibodies: XI International AIDS conference, Vancouver, Canada, 1996
• The use of an Expert System in the management of HIV infection: UARP collaborative meeting, 9/97
• Application of Genotypic Driven Rule-based Expert Artificial Intelligence Computer System in Treatment of Experienced HIV-infected Patients. XIIth International Conference on AIDS. Geneva, 1998
• Long-Term Effectiveness of HAART in a Large Clinical Group and the Role of Viral Resistance in Treatment Failure. XIIth International Conference on AIDS. Geneva, 1998
• The Use of Bioassays in Natural Products. Nutracon, Las Vegas, NV, 7/99.

• Alpha Omega Alpha (1985 - present)
• Orange County Medical Society (1994-95)

• University and Public Service

• Instructor. Physical Examination Course, UCI Medical School, 1990 and 91
• Instructor. Introduction to Medicine Course, UCI Medical School, 1991 and 92
• Lecture. "Chronic Fatigue Syndrome", Department of Medicine Grand Rounds, 1/31/93
• Instructor. Sexually Transmitted Diseases Course, Long Beach Health Department: 5/93, 9/93, 10/93, 2/94, 6/94
• Attending Physician. Infectious Diseases clinic, Since 7/92
• Instructor. Patient-Doctor II course, 1993-94, 94-95
• Lecture. "Sexually Transmitted Diseases and Viral Illnesses", Intensive Review Course in Internal Medicine, 9/93, 9/94, 9/95
• Attending physician. Infectious Disease consult service, 12/92, 6/94,1/96, 1/98
• Attending physician. General Medicine ward service, 4/93, 2/94, 11/94, 2/96, 11/97
• Lecture. "Sexually Transmitted Diseases and Viral Illnesses", Intensive" Review Course in Family Medicine, 6/94
• Department of Medicine Core Lectures. "Sexually Transmitted Diseases" (7/93), "Newly Discovered Infections" (7/94)
• Independent Research Supervisor. Biology 199 students and medicine residents
• College of Medicine Interviewer. Since 1993
• Lecture. "Treatable Viral Infections", Academy of Family Practitioners, 4/95
• Lecture. "Overview of Hepatitis B and C", Huntington Beach Hospital Grand Rounds, 9/14/95
• Lecture. "Pathogenesis of HIV infection"; for the conference, "Infectious Diseases. New Problems, New Treatments and how they affect your practice", 10/95
• Presentation. "Development of a Polyvalent Coxsackie Group B Virus Vaccine", for the J. Wayne Ebrite Infectious Diseases Research Conference, 11/1/95
• Lecture. "Current Concepts of Hepatitis C infections and Therapy", for the Association for Professional Infection Control and Epidemiology, 11/14/95
• Lecture. "Current Research in Chronic Fatigue and Immunodeficiency Syndrome", Department of Medicine Grand Rounds, 1/11/96
• Co-Director. Chronic Fatigue Syndrome and Fibromyalgia Clinic, UCIMC, since 5/96
• Lecture. "New Concepts in the Etiology and Treatment of Chronic Fatigue Syndrome", Scripps Hospital Medical Grand Rounds, 12/11/96
• Lecture. "Alternative and Complementary Therapies in AIDS", AIDS on the Front Line, 4/1/97
• Lecture. "Complementary therapies in AIDS", Fifth Annual HIV/AIDS Advanced Nursing Management Conference, 9/97
• Lecture. "Complementary therapies in AIDS", Westin Hotel, 9/97
• Lecture. "New Concepts in the Diagnosis and Management of Chronic Fatigue Syndrome", Department of Medicine Grand Rounds, 10/97
• Physician consultant. Nutrition/Education/Training committee, Orange County AIDS Services Foundation, Since 4/97
• CME acredited lectures, multiple national sites. "The scientifically-validated benefits of glyconutrients," Since 5/98
• Lecture series, Mechanisms of Disease, Second-year Medical School Class, "Pathogenesis of Sepsis," 1994-1998

• See DM, Tilles JG. Myocarditis. In: Current therapy of infectious disease, Schlossberg D, ed. Mosby-Year Book, Philadelphia, PA, pp. 114-115, 1996
• See DM, Tilles JG. Pericarditis and Myocarditis. In: Infectious Diseases, second edition, Blacklow N, ed. W.B. Saunders, Philadelphia, PA, pp. 246-259 1996
• See DM, Tilles JG. Infections of heart and muscle. In: Clinical Virology, first edition, Richman D, Whitley R, Hayden F, eds. Churchhill Livingstone, New York, pp. 113-125, 1997
• See DM. Endocarditis and Immunosuppression in the ICU. In: Handbook of Medical Intensive Care, first edition, Brenner M, Williams J, eds. Current Clinical Strategies Publishing, Fountain Valley (in press)
• See DM, Tilles JG. Myocarditis. In: Current Therapy in Adult Medicine. Kassirer J, ed. Mosby-Year Book Inc., Philadelphia, PA, 1997, pp 223-224.

1. See DM, Tilles JG. Viral Myocarditis. Reviews of Infectious Diseases 1991;13:951-56
2. See DM, Tilles JG. Treatment of Coxsackievirus A9 Myocarditis in Mice with WIN 54954. AntimicrLob Agents Chemother 1992;36:425-28
3. See DM, Tilles JG. WIN 54954 Treatment of Mice Infected with a Diabetogenic Strain of Group B Coxsackievirus. Antimicrob Agents Chemother 1993;37:1593-98
4. See DM, Tilles JG. Efficacy of a Polyvalent Inactivated-virus Vaccine in Protecting Mice from Infection with Clinical Strains of Group B Coxsackieviruses. Scand J Infect Dis 1994;26:739-47
5. See DM, Tilles JG. Pathogenesis of Viral-induced Diabetes in Mice. J Infect Dis 1995;171:1131-8
6. See DM, Tilles JG. Alpha interferon treatment of patients with Chronic Fatigue Syndrome. Immunological Investigations 1996;25:153-64
7. See DM, Tilles JG. Pathogenesis of viral-induced diabetes. Current Opinions in Infectious Diseases 1996;9:161-164
8. Lina B, Valette M, Foray S, Luciani J, Stagnara J, See DM, Aymard M. Surveillance of Community-Acquired viral infections due to respiratory viruses in Rhone-Alpes (France) during winter 1994-1995. J Clin Microbiol 1996;34:3007-3011
9. See DM, Broumand N, Sahl L, Tilles JG. In vitro effects of Echinacea ginseng on natural killer and antibody-dependent cell cytotoxicity in healthy subjects and chronic fatigue syndrome or acquired immunodeficiency syndrome patients. Immunopharmacology 1997;35:229-235
10. Dube M, Sattler F, Torriani F, See D, Havlir D, Kemper C, Dezfuli M, Bozzette S, Bartok A, Leedom J, McCutchan J. A Randomized study of Clarithromycin Plus Ethambutol, for Treatment and Prevention of Relapse of Disseminated MAC (DMAC) in AIDS. Journal Infect Dis (in press)
11. Beaulieux F, See DM, Leparc-Goffart, Aymard M, Lina B. Use of magnetic Beads versus guanidium thiocyanate-phenol-chloroform RNA extraction followed by polymerase chain reaction for the rapid, sensitive detection of enterovirus RNpiA. Research in Virology 1997;148:11-15
12. Berger M, See DM, Bernhard R, Aymard M, Lina B. Direct in situ reverse transcriptase polymerase chain reaction for the detection of enterovirus genome in liver tissues. J Virol Methods 1997;65:55-66
13. Gupta S, Aggarwhal S, See D, Starr A. Cytokine production by adherent and non-adherent mononuclear cells in Chronic Fatigue Syndrome. J Psych Res 1997;31:149-156
14. See DM, Khemka P, Sahl L, Bui T, Tilles J. The role of natural killer cells in viral infections. Scand J Immunol 1997;46:217-224
15. See DM, Tilles JG. Protection from hepatitis in baby rabbits infected with clinical strains of group B coxsackieviruses by an inactivated-virus vaccine. Proc Nat Soc Exp Bio Med 1997;216:52-56
16. Pazzani M, See D, Schroeder E, Tilles JG. Use of an expert system in the management of HIV infected individuals. J AIDS and Hum Retroviruses 1997;15;356-362
17. See D, See J, Clark T, Tilles J. Successful immunization of mice using liposomes containing inactivated, prototype strains of all six types of coxsackie group B viruses. Vaccine Research 1997;6:27-32
18. Berger M, See D, Bernhard R, Aymard M, Lina B. Detection of viral genome in murine myocardial cells using in situ PCR after infection with a myocardiotropic strain of Coxsackievirus B3. Research in Virology 1997;148:409-416
19. See DM, Tilles JG. Pathogenesis of viral-induced diabetes. Clinical and Diagnostic Virology (in press)
20. Berger M, See D, Aymard M, Lina B. Demonstration of persistent enterovirus in the pancreas of diabetic mice by in situ polymerase chain reaction. Clinical and Diagnostic Virology (in press)
21. Rudich S, Kinkhabwala M, Murray N, See D, Busuttil R, Imigawa D. Successful treatment of mycotic hepatic artery pseudoaneurysms with arterial reconstruction and Liposomal Amphotericin B. Transplantation (in press)
22. See D, Tilles BJ, Hirschman J, Bertacchini C. The in vitro and in vivo immunomodulatory effects of Hansi. Am J Nat Med (in press)
23. See D, Cimoch P, Chou S, Chang J, Tilles J. The in vitro immunomodulatory effects of glyconutrients on peripheral blood mononuclear cells of patients with Chronic Fatigue Syndrome. J Integr Physiol Beh Med (in press)
24. See D, Berman S, Justis J, Broumand N, Chou S, Chang J, Tilles J. A phase I study of the safety of Echinacea angustifolia and its effect on viral load in HIV infected individuals. JANA 1998;1:14-17
25. Khema V, See D, See J, Chou S, Chang J, Tilles J. The efficacy of an oral liposomal hepatitus B and C vaccine in mice. Viral Immunology 1998;11:73-78
26. Dube M, Torriani F, See DM, Havlir D, Kemper C, Leedom J, Tilles J, McCutchan A, Satler, F. Treatment of a clarithromycin-resistant MAC bacteremia in AIDS. Clinical Infectious Diseases (in press).
27. See DM. Complementary Therapies in Arthritis. JANA;1:7-14
28. See, Gurnee K, LeClair M. An In Vitro Screening Study of 196 Natural Products for Toxicity and Efficacy. JANA;25-41
29. Dube M, Torriani F, See D et al. Sucessful short-term suppression of clarithromycin-resistant mycobacterium avium complex bacteremia in AIDS. Clinical Infectious Diseases 1999;28:136-8
30. See DM, Berger M, Lina B, Aymard M, Tilles JG. Pathogenesis of chronic hepatitis in baby rabbits caused by infection with coxsackievirus B5. Viral Immunology (in press).

• Articles in General Readership Magazines and Newspapers

• See DM, Tilles JG. WIN 54954 Treatment of Mice Infected with a Diabetogenic Strain of Group B Coxsackievirus. International Antiviral News, January 1994, vol. 2, no. 1, page 4
• Lathrop R, Steffan N, Raphael M, Deeds-Rubin S, Pazzani M, Cimoch P, See D, Tilles JG. Knowledge-based avoidance of drug-resistant HIV mutants. Proceedings of the AAAI, 1998, pp. 1071-78
• See DM. An overview of glyconutrient use in CFS. CFIDS Chronicle, Sep/Oct 1998, p. 15
• Lathrop R, Steffan N, Raphael M, Deeds-Rubin S, Pazzani M, Cimoch P, See D, Tilles JG. Knowledge-based avoidance of drug-resistant HIV mutants. AI Magazine, Spring 1999, pp. 13-25

• Abstracts and Posters

1. Milefchik E, Leal M, Haubrich R, See D, Bozzette S, Larsen R. High Dose Fluconazole with and without Flucytosine for AIDS Associated Cryptococcal Meningitis. ABSTRACT presented at the IXth International Conference on AIDS. Berlin, June 7-11, 1993
2. Gupta S, See D, Michalewski H, Starr A. Cytokine Production and Movement Related Brain Potentials are Abnormal in Chronic Fatigue Syndrome. ABSTRACT presented at the First National Conference on Chronic Fatigue Syndrome, 10/94
3. Dube M, Sattler F, Torriani F, See D, Havlir D, Kemper C, Dezfuli M, Bozzette S, Bartok A, Leedom J, McCutchan J. A Randomized study of Clarithromycin Plus Ethambutol, for Treatment and Prevention of Relapse of Disseminated MAC(DMAC) in AIDS. ABSTRACT presented at the 35th ICAAC
4. Dube M, Satler F, Torriani F, See D, Havlir D, Kemper C, Dezfuli M, Bozzete S, Bartok A, Leedom J, Tilles J, McCutchan A. Prevention and relapse of MAC bacteremia in AIDS: A Randomized Study of Clarithromycin plus Clofazamine with or without Ethambutol. ABSTRACT presented at the Third Conference on Retroviruses and Opportunistic infections
5. Torriani F, Dube M, Sattler F, See D, Kemper C, Jasura M, McCutchan J, Havlir D and the California Collaborative Treatment Group. A longitudinal analysis of Chlarithromycin susceptibilities and genotypes of Mycobacterium Avium Complex (MAC) blood isolates of AIDS patients treated for MAC bacteremia. ABSTRACT presented at the 36th ICAAC
6. Berger M, Lina B, See D, Aymard M. Detection and localization of enterovirus in liver tissues by in situ PCR. Joint Meeting of the European Group for Rapid Viral Diagnosis, London, England, 12/96
7. Dube M, Torriani F, See D, Havlir D, Kemper C, Leedom J, Tilles J, McCutchan J, Sattler F. Treatment of clarithromycin resistant MAC bacterermia in AIDS. ABSTRACT to be presented at the 37th ICAAC
8. See D. Invited speaker at the 16th International Diabetes Foundation Conference in Helsinki, Finland, July 20-25, 1997. Mouse Models for enteroviral-induced IDDM.
9. Berger M, See D, Lina B. Demonstration of persistent enterovirus in the pancreases of diabetic mice by in situ polymerase chain reaction. Oral presentation at the 16th IDF confrence, Helsinki, Finland, 1997
10. Huang W, See D, Tilles J. The prevalence of Mycoplasma Incognitus in Normal Controls or Patients with AIDS or the Chronic Fatigue Syndrome. ABSTRACT presented at the Amercian Society for Microbiology conference, September 1997
11. Dube M, Torriani F, See D et al. Treatment of clarithromycin resistant MAC bacterermia in AIDS. (37th ICAAC, Toronto, 9/97)
12. See D, Gurnee K, McDaniel C, McDaniel R, Akbapour F, McDaniel B. The efficacy of glyconutrients in three biomarkers of the aging process. (First International Conference on Anti-aging Research, Dec 10-13, 1998, Las Vegas, NV)

• Work in Progress

1. See DM, Kopecka H, Julien R, Keen K, Aymard M, Lina B. Complete Sequence of a Polio type-2 Defective Interfering virus from the Cerebrospinal Fluid of a patient with Postpolio Syndrome (submitted).
2. See DM, Clark T, Tilles JG. Oral Densensitization of coxsackievirus-induced diabetes in a subset of infected mice suggests a dual mechanism of disease pathogenesis (submitted).
3. See DM, Broumand N, Choung S, Tilles JG. Alpha interferon treatement of patients with decreased natural killer cell function (submitted).